

Erratum

Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial – ERRATUM

Allan H. Young, Pierre-Michel Llorca, Andrea Fagiolini, Peter Falkai, Narcís Cardoner, René E. Nielsen, Ola Blomqvist, Yordan Godinov, Benoît Rive, Joris Diels, Siobhán Mulhern-Haughey and Andreas Reif

keywords

Esketamine nasal spray; sensitivity analysis; quetiapine extended release; treatment resistant depression; long-term treatment; erratum.


Access article, distributed under the terms of the Creative Commons Attribution licence (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.

Copyright and usage


© The Author(s), 2025. Published by Cambridge University Press on behalf of Royal College of Psychiatrists. This is an Open

DOI: <https://doi.org/10.1192/bjp.2024.124>, Published by Cambridge University Press: 2 December 2024.

In the original publication of this article, a row in Figure 2 was incorrectly labelled as ‘Odds ratio (95% CI)’:



This should have read ‘Risk Difference (95% CI)’ instead:



The article has been updated to reflect this change, and this erratum published.

Reference

Young AH, Llorca PM, Fagiolini A, Falkai P, Cardoner N, Nielsen RE, Blomqvist O, et al. Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial. *The British Journal of Psychiatry* 2025; **226**(2): 72–8. <https://doi.org/10.1192/bjp.2024.124>.

Allan H. Young; Pierre-Michel Llorca; Andrea Fagiolini; Peter Falkai; Narcis Cardoner; René E. Nielsen; Ola Blomqvist; Yordan Godinov; Benoît Rive; Joris Diels; Siobhán Mulhern-Haughey; Andreas Reif